This is a working overview of Freeze-thaw, written for readers who want more than a one-paragraph summary but less than a textbook.
This page was last updated on 2025-10-25 and is reviewed periodically as new material appears.
Identity and purity are assessed with chromatographic and mass spectrometric techniques. Reversed-phase high-performance liquid chromatography separates the target peptide from related impurities and degradation products, and the resulting retention time is compared against a reference standard. Mass spectrometry, often coupled to liquid chromatography, confirms molecular mass. Amino acid analysis or peptide mapping can provide additional sequence-level confirmation when required. Results are only as reliable as the reference materials used alongside them.
Regulatory treatment varies by country. In the United States, melanotan-2 is not approved for any indication, and products marketed for human use fall outside the approved drug framework. Some other jurisdictions have placed it under prescription controls or listed it as a prohibited or restricted substance. Online listings frequently describe the material as a research chemical, a category that does not carry the same manufacturing and labelling requirements as approved medicines.
Verification of a purchased sample requires documentation linking a batch to a certificate of analysis, and that document should be read for the methods used rather than the headline purity figure. A single chromatographic percentage does not establish identity. Independent laboratories can perform identity and content assays, but no such test establishes that a product is suitable for human use. Claims about efficacy rest largely on small, early studies rather than on replicated controlled trials, and that gap remains open.
Identity testing for a cyclic peptide of this size usually relies on reversed-phase high-performance liquid chromatography coupled to mass spectrometry. The mass spectrum confirms molecular weight, while the chromatographic trace indicates the proportion of related impurities. Tandem mass spectrometry can provide sequence-level information when fragmentation data are compared against a reference standard. Nuclear magnetic resonance is sometimes used to confirm the lactam bridge, although it requires more material and greater operator expertise than routine chromatographic methods.
| Property | Value | Notes |
|---|---|---|
| Solid-state storage | -20 degrees Celsius or lower | Desiccated and protected from light |
| Solution stability | Short and method-dependent | Confirm by stability testing |
| Purity assessment | Reversed-phase HPLC | Reported as area percent |
| Identity confirmation | LC-MS or comparable method | Mass match against expected value |
| Common synonyms | MT-II; melanotan II | Informal and catalogue names |
Identification in laboratories relies on reversed-phase liquid chromatography coupled with tandem mass spectrometry, with product-ion spectra compared against a certified reference standard. High-resolution mass spectrometry supplies accurate mass confirmation, and peptide mapping after enzymatic digestion separates melanotan II from closely related analogues. Quantitation of seized material is complicated by unknown counter-ions and residual trifluoroacetate left from purification. Immunoassays raised against alpha-melanocyte-stimulating hormone can cross-react, so chromatographic confirmation is normally required. Urinary detection windows are short, and reported limits of detection differ substantially between laboratories.
Melanotan II holds no marketing authorisation from the Food and Drug Administration, the European Medicines Agency, the UK Medicines and Healthcare products Regulatory Agency or Australia's Therapeutic Goods Administration. Products sold under that name are treated as unapproved new drugs, and their sale or import is prohibited in several jurisdictions. Other countries classify the peptide as a prescription-only medicine or place it among controlled substances, so the legal position changes with the destination market. No pharmacopoeial monograph supplies an official specification, because the material is not a licensed pharmaceutical. Consequently, products offered online are not manufactured to a shared public standard.
Published research on the compound remains limited. Much of the human data comes from small, early-stage studies rather than large controlled trials, and several questions about effects and variability between individuals remain open. Investigators have examined receptor activity, pigment pathways, and related physiological responses in laboratory and animal models. Findings from those models do not automatically translate to human outcomes. Reviews frequently note the scarcity of rigorous clinical evidence and call for better-characterized study material.
Because the substance circulates mainly through informal markets, verification is a recurring theme in technical discussion. Independent analyses have found that labeled content and actual content can diverge, and that purity varies between samples. Analytical laboratories use reversed-phase chromatography to separate components and mass spectrometry to confirm identity. Isotope-labeled internal standards improve quantification in complex matrices. Such methods describe what a sample contains but say nothing about its sterility, lawful status, or suitability for any use. Open questions remain about how consistently testing is applied across the supply chain.
Regulatory treatment of this peptide varies by country. It holds no marketing authorization as a medicine in the United States, the European Union, or most other jurisdictions. Some countries classify products containing it as prescription-only or unlicensed medicines, which restricts lawful supply. Authorities have issued public notices warning that unregulated products may contain undeclared or incorrect ingredients. The molecule also appears on prohibited lists for competitive sport. These measures address supply oversight rather than any approved therapeutic role.
Routine characterisation relies on reversed-phase high-performance liquid chromatography with ultraviolet detection near 214 nanometres, using a C18 column and a water-acetonitrile gradient containing trifluoroacetic acid. Electrospray ionisation mass spectrometry confirms the expected molecular mass and can reveal truncated or oxidised by-products that co-elute poorly. Sequence and stereochemistry require additional work, such as peptide mapping or amino acid analysis, because a chromatographic purity figure alone does not distinguish a diastereomer from the target peptide. Independent testing of research-grade material frequently shows measured content below the stated label, so a certificate of analysis is best read together with the method that produced it.
Melanotan-2 is handled in the laboratory as a lyophilised powder that dissolves readily in water, dimethyl sulfoxide and dimethylformamide, with limited solubility in ethanol. Stock solutions prepared in an organic solvent often precipitate when diluted into aqueous buffer, so gradual dilution with mixing is standard practice. The peptide carries a tryptophan residue and a histidine residue, both sensitive to oxidation and to alkaline conditions. Working solutions are therefore kept near neutral to slightly acidic pH, protected from light, and consumed within the same working session whenever that is practical.
=== 1. FC Lokomotive (1966–1990) === East German football went through a general reorganization in 1965, creating football clubs as centres of high-level football, during which the football department of SC Leipzig was separated from the sports club and reformed into football club 1. FC Lokomotive Leipzig, while rival Chemie Leipzig continued as a Betriebssportgemeinschaft (BSG), or corporate team. Like most East German clubs, it was assigned to a publicly owned enterprise as its "sponsor". In the case of Lokomotive, the providing enterprise was Deutsche Reichsbahn—the East German state railways—hence the name. The club's fortunes improved somewhat as they almost always finished well up the league table, but they were unable to win the top honour in the DDR-Oberliga, with losing final appearances in 1967, 1986, and 1988. Lok earned a clutch of East German Cups (FDGB Pokal) with victories in 1976, 1981, 1986, and 1987, against failed appearances in the Cup final in 1970, 1973, and 1977. They also won the UEFA Intertoto Cup in 1966 and made an appearance in the 1987 final of the European Cup Winners' Cup, falling 0–1 to Johan Cruyff's Ajax after a Marco van Basten goal.
=== Books === Decoding Darkness: The Search for the Genetic Causes of Alzheimer's Disease. with Ann B, Parson. New York: Perseus Publishing, 2000. Super Brain: Unleashing the Explosive Power of Your Mind to Maximize Health, Happiness, and Spiritual Well-Being. New York: Harmony Books, Random House, 2012. Super Genes: Unlock the Astonishing Power of Your DNA for Optimum Health and Well-Being. New York: Harmony Books, Random House, 2015. The Healing Self: A Revolutionary New Plan to Supercharge Your Immunity and Stay Well for Life. New York: Harmony, Random House, 2018.
Historians have explored how the Napoleonic wars became total wars. Most historians argue that the escalation in size and scope came from two sources. First was the ideological clash between revolutionary/egalitarian and conservative/hierarchical belief systems. Second was the emergence of nationalism in France, Germany, Spain, and elsewhere, that made these "people's wars" instead of contests between monarchs. Bell has argued that even more important than ideology and nationalism were the intellectual transformations in the culture of war that came about through the Age of Enlightenment. One factor, he says, is that war was no longer a routine event but a transforming experience for societies—a total experience. Secondly, the military emerged in its own right as a separate sphere of society distinct from the ordinary civilian world. The French Revolution made every civilian a part of the war machine, either as a soldier through universal conscription, or as a vital cog in the home front machinery supporting and supplying the army. Out of that, says Bell, came "militarism", the belief that the military role was morally superior to the civilian role in times of great national crisis. The fighting army represented the essence of the nation's soul. As Napoleon proclaimed, "It is the soldier who founds a Republic and it is the soldier who maintains it." Napoleon said on his career "I closed the gulf of anarchy and brought order out of chaos. I rewarded merit regardless of birth or wealth, wherever I found it.
=== MeSH D12.644.360 – intracellular signaling peptides and proteins === MeSH D12.644.360.011 – activating transcription factor 6 MeSH D12.644.360.024 – adaptor proteins, signal transducing MeSH D12.644.360.024.264 – caveolin 1 MeSH D12.644.360.024.272 – caveolin 2 MeSH D12.644.360.024.280 – cortactin MeSH D12.644.360.024.295 – crk-associated substrate protein MeSH D12.644.360.024.297 – grb2 adaptor protein MeSH D12.644.360.024.298 – grb7 adaptor protein MeSH D12.644.360.024.300 – grb10 adaptor protein MeSH D12.644.360.024.301 – interferon-stimulated gene factor 3 MeSH D12.644.360.024.301.500 – interferon-stimulated gene factor 3, alpha subunit MeSH D12.644.360.024.301.500.500 – stat1 transcription factor MeSH D12.644.360.024.301.500.750 – stat2 transcription factor MeSH D12.644.360.024.301.750 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.303 – interferon regulatory factors MeSH D12.644.360.024.303.124 – interferon regulatory factor-1 MeSH D12.644.360.024.303.249 – interferon regulatory factor-2 MeSH D12.644.360.024.303.374 – interferon regulatory factor-3 MeSH D12.644.360.024.303.437 – interferon regulatory factor-7 MeSH D12.644.360.024.303.500 – interferon-stimulated gene factor 3, gamma subunit MeSH D12.644.360.024.305 – pii nitrogen regulatory proteins MeSH D12.644.360.024.307 – paxillin MeSH D12.644.360.024.311 – protein inhibitors of activated STAT MeSH D12.644.360.024.313 – 14-3-3 proteins MeSH D12.644.360.024.318 – proto-oncogene proteins c-crk MeSH D12.644.360.024.326 – proto-oncogene proteins c-vav MeSH D12.644.360.024.334 – smad proteins MeSH D12.644.360.024.334.200 – smad proteins, inhibitory MeSH D12.644.360.024.334.200.600 – smad6 protein MeSH D12.644.360.024.334.200.700 – smad7 protein MeSH D12.644.360.024.334.500 – smad proteins, receptor-regulated MeSH D12.644.360.024.334.500.100 – smad1 protein MeSH D12.644.360.024.334.500.200 – smad2 protein MeSH D12.644.360.024.334.500.300 – smad3 protein MeSH D12.644.360.024.334.500.500 – smad5 protein MeSH D12.644.360.024.334.500.800 – smad8 protein MeSH D12.644.360.024.334.750 – smad4 protein MeSH D12.644.360.024.342 – stat transcription factors MeSH D12.644.360.024.342.100 – stat1 transcription factor MeSH D12.644.360.024.342.200 – stat2 transcription factor MeSH D12.644.360.024.342.300 – stat3 transcription factor MeSH D12.644.360.024.342.400 – stat4 transcription factor MeSH D12.644.360.024.342.500 – stat5 transcription factor MeSH D12.644.360.024.342.600 – stat6 transcription factor MeSH D12.644.360.024.374 – suppressor of cytokine signaling proteins MeSH D12.644.360.024.500 – tumor necrosis factor receptor-associated peptides and proteins MeSH D12.644.360.024.500.500 – tnf receptor-associated factor 1 MeSH D12.644.360.024.500.750 – tnf receptor-associated factor 2 MeSH D12.644.360.024.500.875 – tnf receptor-associated factor 3 MeSH D12.644.360.024.500.937 – tnf receptor-associated factor 5 MeSH D12.644.360.024.500.968 – tnf receptor-associated factor 6 MeSH D12.644.360.050 – adenylate cyclase MeSH D12.644.360.075 – apoptosis regulatory proteins MeSH D12.644.360.075.311 – apoptosis inducing factor MeSH D12.644.360.075.405 – caspases MeSH D12.644.360.075.405.200 – caspase 1 MeSH D12.644.360.075.437 – inhibitor of apoptosis proteins MeSH D12.644.360.075.437.500 – neuronal apoptosis-inhibitory protein MeSH D12.644.360.075.437.750 – x-linked inhibitor of apoptosis protein MeSH D12.644.360.075.718 – proto-oncogene proteins c-bcl-2 MeSH D12.644.360.075.718.100 – bcl-associated death protein MeSH D12.644.360.075.718.400 – bcl-2-associated x protein MeSH D12.644.360.075.718.750 – bcl-2 homologous antagonist-killer protein MeSH D12.644.360.075.718.937 – bcl-x protein MeSH D12.644.360.075.718.968 – bh3 interacting domain death agonist protein MeSH D12.644.360.100 – ca(2+)-calmodulin dependent protein kinase MeSH D12.644.360.100.500 – myosin-light-chain kinase MeSH D12.644.360.150 – casein kinases MeSH D12.644.360.150.300 – casein kinase i MeSH D12.644.360.150.300.100 – casein kinase ialpha MeSH D12.644.360.150.300.200 – casein kinase idelta MeSH D12.644.360.150.300.300 – casein kinase iepsilon MeSH D12.644.360.150.600 – casein kinase ii MeSH D12.644.360.200 – cyclic nucleotide-regulated protein kinases MeSH D12.644.360.200.125 – cyclic amp-dependent protein kinases MeSH D12.644.360.200.125.500 – beta-adrenergic receptor kinase MeSH D12.644.360.200.150 – cyclic gmp-dependent protein kinases MeSH D12.644.360.200.575 – protamine kinase MeSH D12.644.360.250 – cyclin-dependent kinases MeSH D12.644.360.250.067 – cdc2-cdc28 kinases MeSH D12.644.360.250.067.249 – cdc2 protein kinase MeSH D12.644.360.250.067.500 – cdc28 protein kinase, s cerevisiae MeSH D12.644.360.250.067.875 – cyclin-dependent kinase 5 MeSH D12.644.360.250.067.900 – cyclin-dependent kinase 9 MeSH D12.644.360.250.323 – cyclin-dependent kinase 2 MeSH D12.644.360.250.451 – cyclin-dependent kinase 4 MeSH D12.644.360.250.515 – cyclin-dependent kinase 6 MeSH D12.644.360.250.580 – maturation-promoting factor MeSH D12.644.360.250.580.500 – cdc2 protein kinase MeSH D12.644.360.275 – eif-2 kinase MeSH D12.644.360.287 – focal adhesion protein-tyrosine kinases MeSH D12.644.360.300 – glycogen synthase kinases MeSH D12.644.360.300.500 – glycogen synthase kinase 3 MeSH D12.644.360.325 – gtp-binding protein regulators MeSH D12.644.360.325.150 – gtpase-activating proteins MeSH D12.644.360.325.150.100 – chimerin proteins MeSH D12.644.360.325.150.100.200 – chimerin 1 MeSH D12.644.360.325.150.300 – eukaryotic initiation factor-5 MeSH D12.644.360.325.150.500 – ras gtpase-activating proteins MeSH D12.644.360.325.150.500.460 – neurofibromin 1 MeSH D12.644.360.325.150.500.500 – p120 gtpase activating protein MeSH D12.644.360.325.150.750 – rgs proteins MeSH D12.644.360.325.225 – guanine nucleotide dissociation inhibitors MeSH D12.644.360.325.300 – guanine nucleotide exchange factors MeSH D12.644.360.325.300.200 – eukaryotic initiation factor-2b MeSH D12.644.360.325.300.300 – guanine nucleotide-releasing factor 2 MeSH D12.644.360.325.300.450 – proto-oncogene proteins c-vav MeSH D12.644.360.325.300.600 – ral guanine nucleotide exchange factor MeSH D12.644.360.325.300.700 – ras guanine nucleotide exchange factors MeSH D12.644.360.325.300.700.500 – ras-grf1 MeSH D12.644.360.325.300.700.700 – son of sevenless proteins MeSH D12.644.360.325.300.700.700.600 – son of sevenless protein, drosophila MeSH D12.644.360.325.300.700.700.630 – sos1 protein MeSH D12.644.360.350 – guanylate cyclase MeSH D12.644.360.375 – heterotrimeric gtp-binding proteins MeSH D12.644.360.375.100 – gtp-binding protein alpha subunits MeSH D12.644.360.375.100.100 – gtp-binding protein alpha subunits, g12-g13 MeSH D12.644.360.375.100.200 – gtp-binding protein alpha subunits, gi-go MeSH D12.644.360.375.100.200.500 – gtp-binding protein alpha subunit, gi2 MeSH D12.644.360.375.100.300 – gtp-binding protein alpha subunits, gq-g11 MeSH D12.644.360.375.100.400 – gtp-binding protein alpha subunits, gs MeSH D12.644.360.375.520 – gtp-binding protein beta subunits MeSH D12.644.360.375.730 – gtp-binding protein gamma subunits MeSH D12.644.360.375.940 – transducin MeSH D12.644.360.376 – i-kappa b kinase MeSH D12.644.360.378 – i-kappa b proteins MeSH D12.644.360.381 – intracellular calcium-sensing proteins MeSH D12.644.360.381.249 – calmodulin MeSH D12.644.360.381.311 – calnexin MeSH D12.644.360.381.374 – calreticulin MeSH D12.644.360.381.437 – gelsolin MeSH D12.644.360.381.500 – neuronal calcium-sensor proteins MeSH D12.644.360.381.500.124 – guanylate cyclase-activating proteins MeSH D12.644.360.381.500.249 – hippocalcin MeSH D12.644.360.381.500.374 – Kv channel-interacting proteins MeSH D12.644.360.381.500.500 – neurocalcin MeSH D12.644.360.381.500.750 – recoverin MeSH D12.644.360.400 – map kinase kinase kinases MeSH D12.644.360.400.100 – map kinase kinase kinase 1 MeSH D12.644.360.400.200 – map kinase kinase kinase 2 MeSH D12.644.360.400.300 – map kinase kinase kinase 3 MeSH D12.644.360.400.400 – map kinase kinase kinase 4 MeSH D12.644.360.400.500 – map kinase kinase kinase 5 MeSH D12.644.360.400.800 – proto-oncogene proteins c-mos MeSH D12.644.360.400.842 – raf kinases MeSH D12.644.360.400.842.249 – oncogene proteins v-raf MeSH D12.644.360.400.842.374 – proto-oncogene proteins b-raf MeSH D12.644.360.400.842.500 – proto-oncogene proteins c-raf MeSH D12.644.360.440 – mitogen-activated protein kinase kinases MeSH D12.644.360.440.100 – map kinase kinase 1 MeSH D12.644.360.440.200 – map kinase kinase 2 MeSH D12.644.360.440.300 – map kinase kinase 3 MeSH D12.644.360.440.400 – map kinase kinase 4 MeSH D12.644.360.440.500 – map kinase kinase 5 MeSH D12.644.360.440.600 – map kinase kinase 6 MeSH D12.644.360.440.700 – map kinase kinase 7 MeSH D12.644.360.450 – mitogen-activated protein kinases MeSH D12.644.360.450.169 – extracellular signal-regulated map kinases MeSH D12.644.360.450.169.500 – mitogen-activated protein kinase 1 MeSH D12.644.360.450.169.750 – mitogen-activated protein kinase 3 MeSH D12.644.360.450.169.875 – mitogen-activated protein kinase 6 MeSH D12.644.360.450.169.937 – mitogen-activated protein kinase 7 MeSH D12.644.360.450.340 – jnk mitogen-activated protein kinases MeSH D12.644.360.450.340.500 – mitogen-activated protein kinase 8 MeSH D12.644.360.450.340.750 – mitogen-activated protein kinase 9 MeSH D12.644.360.450.340.800 – mitogen-activated protein kinase 10 MeSH D12.644.360.450.835 – p38 mitogen-activated protein kinases MeSH D12.644.360.450.835.200 – mitogen-activated protein kinase 11 MeSH D12.644.360.450.835.400 – mitogen-activated protein kinase 12 MeSH D12.644.360.450.835.600 – mitogen-activated protein kinase 13 MeSH D12.644.360.450.835.800 – mitogen-activated protein kinase 14 MeSH D12.644.360.525 – monomeric gtp-binding proteins MeSH D12.644.360.525.100 – adp-ribosylation factors MeSH D12.644.360.525.100.100 – ADP-ribosylation factor 1 MeSH D12.644.360.525.400 – rab gtp-binding proteins MeSH D12.644.360.525.400.025 – rab1 gtp-binding proteins MeSH D12.644.360.525.400.050 – rab2 gtp-binding protein MeSH D12.644.360.525.400.100 – rab3 gtp-binding proteins MeSH D12.644.360.525.400.100.100 – rab3a gtp-binding protein MeSH D12.644.360.525.400.150 – rab4 gtp-binding proteins MeSH D12.644.360.525.400.200 – rab5 gtp-binding proteins MeSH D12.644.360.525.450 – ral gtp-binding proteins MeSH D12.644.360.525.462 – ran gtp-binding protein MeSH D12.644.360.525.475 – rap gtp-binding proteins MeSH D12.644.360.525.475.100 – rap1 gtp-binding proteins MeSH D12.644.360.525.500 – ras proteins MeSH D12.644.360.525.500.300 – oncogene protein p21(ras) MeSH D12.644.360.525.500.600 – proto-oncogene proteins p21(ras) MeSH D12.644.360.525.700 – rho gtp-binding proteins MeSH D12.644.360.525.700.050 – cdc42 gtp-binding protein MeSH D12.644.360.525.700.050.500 – cdc42 gtp-binding protein, saccharomyces cerevisiae MeSH D12.644.360.525.700.100 – rac gtp-binding proteins MeSH D12.644.360.525.700.100.100 – rac1 gtp-binding protein MeSH D12.644.360.525.700.200 – rhoa gtp-binding protein MeSH D12.644.360.525.700.300 – rhob gtp-binding protein MeSH D12.644.360.543 – olfactory marker protein MeSH D12.644.360.562 – phosphatidylethanolamine binding protein MeSH D12.644.360.581 – phospholipase c gamma MeSH D12.644.360.600 – ribosomal protein s6 kinases MeSH D12.644.360.600.249 – ribosomal protein s6 kinases, 70-kda MeSH D12.644.360.600.500 – ribosomal protein s6 kinases, 90-kda
By 2015, industry analysts and academic researchers agreed, that the sky-high price of orphan drugs, such as eculizumab, was not related to research, development and manufacturing costs. Their price is arbitrary and they have become more profitable than traditional medicines.Public resources went into understanding the molecular basis of the disease, public resources went into the technology to make antibodies and finally, Alexion, to their credit, kind of picked up the pieces.
Sources: en.wikipedia.org
Sixth Street generally forms the southern boundary of campus, with many of the single-family homes south of the street rented to students. A Computer Science department webcam provides a live view of the campus from the top of the Gould-Simpson building, the tallest classroom building on campus at 10 stories.
=== Intra-articular injection === It is used to treat knee pain in patients with osteoarthritis who have not received relief from other treatments. It is injected into the joint capsule, to act as both a shock absorber and a lubricant for the joint. Thus sodium hyaluronate is used as a viscosupplement, administered through a series of injections into the knee, increasing the viscosity of the synovial fluid, which helps lubricate, cushion and reduce pain in the joint. It is generally used as a last resort before surgery and provides symptomatic relief, by recovering the viscoelasticity of the articular fluid, and by stimulating new production of synovial fluid. Use of sodium hyaluronate may reduce the need for joint replacement. Injections appear to increase in effectiveness over the course of four weeks, reaching a peak at eight weeks and retaining some effectiveness at six months, with greater benefit for osteoarthritis than oral analgesics. It may also be effective when used with the ankle joint.
Of those who failed to meet weight qualifications but still entered the military, 80% left the military before completing their first term of enlistment. In light of these developments, organizations such as Mission: Readiness, made up of retired generals and admirals, have advocated for focusing on childhood health education to combat obesity's effect on the military.
== Condensation polymerization == Step-growth polymerization and condensation polymerization are two different concepts, not always identical. In fact polyurethane polymerizes with addition polymerization (because its polymerization produces no small molecules), but its reaction mechanism corresponds to a step-growth polymerization. The distinction between addition polymerization and condensation polymerization was introduced by Wallace Carothers in 1929, and refers to the type of products, respectively:
The Viking landers recorded atmospheric pressures ranging from below 7 millibars (0.0068 bars) to over 10 millibars (0.0108 bars) over the Martian year, leading to the conclusion that atmospheric pressure varies by 30 percent during the Martian year because carbon dioxide condenses and sublimes at the polar caps. Martian winds generally blow more slowly than expected, scientists had expected them to reach speeds of several hundred miles an hour from observing global dust storms, but neither lander recorded gusts over 120 kilometers (74 miles) an hour, and average velocities were considerably lower. Nevertheless, the orbiters observed more than a dozen small dust storms. The Viking landers detected nitrogen in the atmosphere for the first time, and that it was a significant component of the Martian atmosphere. There was speculation from the atmospheric analysis that the atmosphere of Mars used to be much denser. The Soviets did not match the Martian lander achievements of NASA, but did claim the title of the first lander.
Sources: en.wikipedia.org
== Allergies == Plantain and banana allergies occur with typical characteristics of food allergy or latex fruit syndrome, including itching and mild swelling of the lips, tongue, palate or throat, skin rash, stomach complaints or anaphylactic shock. Among more than 1000 proteins identified in Musa species were numerous previously described protein allergens.
In 2007, a pet food recall was initiated by Menu Foods and other pet food manufacturers who had found their products had been contaminated and caused serious illnesses or deaths in some of the animals that had eaten them. In March 2007, the US Food and Drug Administration reported finding white granular melamine in the pet food, in samples of white granular wheat gluten imported from a single source in China, Xuzhou Anying Biologic Technology as well as in crystalline form in the kidneys and in urine of affected animals. Further vegetable protein imported from China was later implicated. In April 2007, The New York Times reported that the addition of "melamine scrap" into fish and livestock feed to give the false appearance of a higher level of protein was an "open secret" in many parts of mainland China, reporting that this melamine scrap was being produced by at least one plant processing coal into melamine. Four days later, the New York Times reported that, despite the widely reported ban on melamine use in vegetable proteins in mainland China, at least some chemical manufacturers continued to report selling it for use in animal feed and in products for human consumption. Li Xiuping, a manager at Henan Xinxiang Huaxing Chemical in Henan Province, stated, "Our chemical products are mostly used for additives, not for animal feed.
=== Canine osteoarthritis === LTCI increases the immune response to foreign antigens and dampens the immune-mediated response to self-antigens by increasing the number of precursors of a regulatory T-Cell population. In a double-blind placebo-controlled study, 11 of the 12 LTCI-treated canines had a 40 percent increase in function while the placebo group had a 17 percent decrease in function. Following the study, LTCI was approved by the USDA to treat osteoarthritis in dogs in 2016.
Flutamide acts as a selective, competitive, silent antagonist of the androgen receptor (AR). Its active form, hydroxyflutamide, has between 10- and 25-fold higher affinity for the AR than does flutamide, and hence is a much more potent AR antagonist in comparison. However, at high concentrations, unlike flutamide, hydroxyflutamide is able to weakly activate the AR. Flutamide has far lower affinity for the AR than do steroidal antiandrogens like spironolactone and cyproterone acetate, and it is a relatively weak antiandrogen in terms of potency by weight, but the large dosages at which flutamide is used appear to compensate for this. In accordance with its selectivity for the AR, flutamide does not interact with the progesterone, estrogen, glucocorticoid, or mineralocorticoid receptor, and possesses no intrinsic progestogenic, estrogenic, glucocorticoid, or antigonadotropic activity. However, it can have some indirect estrogenic effects via increased levels of estradiol secondary to AR blockade, and this involved in the gynecomastia it can produce. Because flutamide does not have any estrogenic, progestogenic, or antigonadotropic activity, the medication does not cause menstrual irregularities in women. This is in contrast to steroidal antiandrogens like spironolactone and cyproterone acetate. Similarly to nilutamide, bicalutamide, and enzalutamide, flutamide crosses the blood–brain barrier and exerts central antiandrogen actions.
Sources: en.wikipedia.org
Laboratory confirmation typically combines retention time matching on a chromatographic system with mass measurement. A reference standard of known identity is needed for a meaningful comparison. Sequence-level techniques can add further confirmation.
There is no single harmonised standard governing these products, and manufacturing conditions differ. Impurities may include truncated sequences, oxidation products, residual solvents, and counter-ions. Independent testing is often the only way to characterise a given lot.
Reported studies have looked at pigmentation, photoprotection, and metabolic or appetite-related endpoints in small experimental settings. Much of the evidence base is early-stage and limited in size. Questions about long-term effects and clinical relevance remain open.
Mass spectrometry combined with liquid chromatography provides both molecular weight confirmation and a measure of related impurities. Tandem mass spectrometry adds sequence information. A purity percentage reported without a mass measurement does not confirm what the material is.